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Production and employment impacts of new technologies 
– Analysis for biotechnology 
 
Sven Wydra1 
Fraunhofer Institute for Systems and Innovation Research 
sven.wydra@isi.fraunhofer.de 
 
Abstract 
Biotechnology is often regarded as a key technology with high potential for far-reaching 
social, environmental and economic impacts. Among others, the development and 
diffusion of biotechnology may have considerable economic effects on production and 
employment. This paper analyzes the economic impacts of different diffusion paths of 
biotechnology in some major application fields. Bottom-up technology information from 
literature, expert judgements and explicit scenario assumptions for various impact factors 
are combined and integrated in an input-output framework to calculate direct and indirect 
production and employment effects. The impact on net production and employment differs 
greatly between the different application sectors and depends on the respective importance 
of the various impact mechanisms. The indirect economic effects are rather high and 
exceed direct economic effects. These findings show the importance of a bottom-up 
approach as well as the consideration of indirect economic effects for appropriate analyses 
of the impact of biotechnology. 
Keywords: economic impacts of technologies; employment effects; input-output model; 
biotechnology;  
JEL-classification: C67, O14; O33; J23 
 
 
 
                                                            
1  This paper draws on the doctoral thesis of the author at the University of Hohenheim, Department of 
Economic Theory 520H. The results were presented and discussed at the FZID PhD Workshop 2009, CC 
Innovation & Knowledge. 
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1. Introduction 
Biotechnology is often regarded as a key technology with high potential for far-reaching 
social, environmental and economic impacts. Applications are spread across a wide range 
of industries like pharmaceuticals, health care diagnostics, chemicals, agriculture, food, 
materials technology, energy, environmental monitoring etc. Consequently, biotechnology 
is considered to have strategic importance for knowledge-based economies. Many nations 
try to develop biotechnology capabilities to realize economic impacts (Arundel 2003). 
However, insights about potential economic impacts on a meso- or even macroeconomic 
level are still limited, since there are major methodological challenges to quantifying 
possible paths of diffusion and economic impacts of biotechnology. Most of the economic 
effects from technologies with wide applications like biotechnology can be expected due to 
its diffusion and adoption by user firms in application industries (OECD 2005). Modelling 
seems to be a reasonable approach towards considering impacts in application sectors and 
complex interactions within an economy’s set of markets. But several difficulties arise, 
since adequate data sources for this process technology with related applications in very 
diverse sectors are scarce. Moreover, the impact of biotechnology may differ widely 
between the various sectors, as the techniques and applications used can vary quite 
substantially, and different impact mechanisms may gain importance (Rose/McNiven 
2007). In order to analyze the net effects of biotechnology, negative economic impacts 
have also to be taken into account, e.g. due to the (relative) "shrinkage" of conventional 
value chains or negative budget effects, caused by extra costs for the provision and 
application of biotechnology processes (e. g. subsidies and tax exemptions for biofuels).  
Only few modelling approaches which take biotechnological diffusion in several 
application sectors into account currently exist. Menrad et al. (2003) and Nusser/Wydra 
(2007) analyze direct and indirect gross production and gross employment related to 
biotechnology diffusion. An important starting point for analyzing net impacts is the work 
of Dewick et al. (2006). They estimate the impact of biotechnology on economic structure 
with expert judgements for potential changes of input-output coefficients for the EU, USA 
and China in 2020 and 2050. While this analysis provides specific insights on the impact in 
various application sectors and considers differences between regions, it focuses solely on 
input changes in production chains. 
The objective of the present study is to provide additional insights into the economic 
impact of biotechnology and to assess the net production and employment impacts of 
biotechnology diffusion in Germany. Economic impacts in several applications fields of 
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biotechnology are modelled for different scenarios with a time horizon to 2020. Bottom-up 
technology information from literature, expert judgements and explicit scenario 
assumptions for various impact factors (e.g. diffusion rate, oil and feedstock prices, 
political measures) are combined and integrated in an input-output framework. The input-
output model allows a disaggregated analysis and captures some of the indirect economic 
effects in other sectors. In order to capture the cross-sectional character of biotechnology, 
heterogeneous application sectors (biopolymers, bioethanol, biopharmaceuticals and 
biotechnological fine/specialty chemicals) in respect to type of dominant innovation, 
regulatory and political framework conditions, diffusion barriers as well as linkages to 
biomass production are selected for the analyses.  
This approach enables us to study the differences in impact between application sectors 
and the importance of different impact factors, like diffusion rate or oil and feedstock 
prices. From a methodological point of view, the direct combination of different data 
sources, techno-economic studies as well as expert judgements builds on a broader 
information basis than previous studies for biotechnology. The basic input-output model is 
extended in several ways to take changes in demand and constraints on agricultural 
markets into account. 
Section 2 begins with a short overview of the theoretical arguments regarding economic 
impacts of emerging technologies and discusses these arguments for the case of 
biotechnology. In section 3 the methodology applied in this study to measure diffusion and 
economic impacts of biotechnology is introduced. Section 4 presents the results of current 
and potential diffusion paths, and related production and employment figures are given in 
section 5. Finally, section 6 summarises the main findings and discusses the research 
results. 
 
2. Economic impact mechanisms of biotechnology 
The overall impact of technologies on production and employment results from the 
interaction of different impact mechanisms (e.g. Vivarelli 1995; Pianta 2005; Walz 2006; 
Zeddies 2006). In the case of employment, on the one hand it is claimed that technological 
change mainly increases the potential for rationalisation, which leads to displacement of 
labour. On the other hand, various market compensation mechanisms can counterbalance 
the initial labour-saving impact of process innovation (Vivarelli 1995, Petit 1995, Pianta 
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2005). It is possible to discern various compensation routes that alleviate the labour-saving 
effects (Hagemann 1995): 
• New markets for product innovations extend the total demand. 
• Cost reductions resulting from more efficient production processes are passed on to 
the consumers via price reductions or increases in wages. In effect, this raises 
overall demand. 
• The machines and aggregates required for these modern production processes have 
to be newly engineered. This leads to more jobs in the capital goods sector. 
• The use of new technologies improves the international competitiveness of 
innovative domestic companies, thus positively influencing domestic value added 
and employment. 
• In addition, structural effects may occur (Walz 2006). The labour intensities and the 
import intensities of the value chains of new products and process can differ and 
lead to higher or lower value added and employment.  
Therefore, it is not possible to deduce the macro-economic impacts from an isolated view 
of some partial effects. Theoretical paradigms differ strongly in the view, which impact 
mechanisms dominate (Vivarelli 1995). Moreover the effects depend on the specific 
technology and prevailing conditions of competition, price and wage rigidities, investment 
climate etc. (Vivarelli 2007).  
In the case of biotechnology, there is a great variety in the produced outputs, the related 
advantages of biotechnological methods vary and the framework conditions between 
application sectors differ greatly (e.g. highly regulated sectors like pharmaceuticals vs. 
textile etc.). Discussions by Dewick et al. (2004) demonstrate that advances in 
biotechnology are likely to be reflected in increased demand in some sectors (e.g. 
pharmaceuticals, specialty chemicals). Instead, Rose/McNiven (2007) point out that an 
important part of the impact of biotechnology is the result of substitution effects, such as 
changes in supply chains (e.g. substitution of raw materials or energy sources) and mainly 
refers to sectors with high demands for raw materials (e.g. bulk chemicals). Especially in 
this case, the effects triggered by the use of biotechnology are played out on a meso-
economic level, where the more technology-related impact mechanisms dominate. Another 
important aspect is the rather low impact on labour productivity and cost reductions 
(Freeman 2003; Nusser et al. 2007a; Hopkins et al. 2007). In contrast, biotechnological 
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production costs may even be higher for some applications. In these cases the diffusion of 
biotechnology is usually triggered by political measures. The additional costs (budget 
effect) incurred for the provision and use of products from biomass compared to traditional 
products must be compensated for by spending less elsewhere, e.g. through decreasing 
private consumption expenditure as a result of higher prices for fuels, in the case of 
bioethanol.  
Besides the importance of different impact mechanisms, two aspects have to be taken into 
account in modelling biotechnology impact. Firstly, biotechnology measurement is still in 
its early stages and useful indicators for the impacts of biotechnology (e.g. productivity, 
value added, price effects) which can be linked to macro-economic models are still lacking 
(OECD 2005, Rose/McNiven 2007). The advantage of various models to include some 
mechanisms, like substitution due to price effects in the case of general equilibrium 
models, cannot be currently realized for biotechnology. Secondly, in some sectors 
biotechnological development is still in the initial stages and technological improvements 
are likely in the future, which greatly influence the related economic impact. 
Consequently, technological progress should be considered in any prospective economic 
analysis.   
These various aspects have considerable consequences for the study design and modelling 
approach: instead of a highly aggregated macro-economic model, a modelling approach is 
required which is based on technology-specific information and analyzes the effects of 
changes in demand on sectoral structures, including the related indirect effects on the 
supply chains. As the sectors differ in work intensities and import propensities, overall 
employment may change. In addition, cost and budget effects should not be neglected, 
because covering higher costs for the users or public promotion necessitate compensation 
in other places. Moreover, developments in international competitiveness may change the 
trade balance and domestic production.  
 
3. Methodological approach 
In order to take due consideration of the aspects discussed above, this study assesses the 
impact of biotechnology in a bottom-up approach from a techno-economic perspective. 
The results are integrated in an input-output framework to assess indirect economic effects 
in other sectors. The study design consists of several steps: firstly, a set of scenarios is 
developed for biotechnological development and price paths for oil and biomass. Secondly, 
a detailed analysis of biotechnology in different application sectors is conducted and the 
different impact mechanisms are assessed. Thirdly, the results of the first two steps are 
integrated in an input-output-model to analyze (net) economic effects. The overall 
methodological approach and data sources are summarised in figure 1 and discussed in 
more detail below, after the description of the selected application sectors.   
 
Figure 1: Schematic block diagram of the overall modelling setup 
Data sources
Basic model and 
adjustments
Calculations
Results
Federal Statistical 
Office 
Expert judgements Techno-economic 
and IO studies
Energy and agri-
cultural statistics
Basic IO tables
4 new biotechno-
logical and 4 sub-
stitute IO sectors
Consumption 
vectors for IO 
sectors
Scenario data for 
prices, productivity 
and land availability
Calculation of 
impacts through 
substitution
Calculation of 
household budgets 
and consumption
Productivity and 
employment 
impact
 
Due to the utilization of biotechnology in many sectors and restraints in data availability, 
the study focuses on four different application fields. In their entirety, but also in each 
single case, selected applications should represent a significant proportion of the economy.  
Four heterogeneous application sectors are selected to study the cross-sectional impact of 
biotechnology: biopolymers, bioethanol, biopharmaceuticals and biotechnological 
fine/specialty chemicals. These applications differ widely in many aspects, e.g. the specific 
advantage of biotechnology, the type of innovation (product vs. process), the effect on 
production costs, input demand of biomass sector, state of technical development and 
sectoral context. Table 1 summarizes main attributes of biotechnology in the different 
sectors. Although the overall economic impact of biotechnology cannot be covered by this 
 
6 
 
 7 
 
selection, the various application fields at least represent the cross-sectional character of 
biotechnology. 
 
Table 1: Characterization of the selected biotechnology application fields 
  Biopolymers  Bioethanol  Fine and 
specialty 
chemicals 
Biopharmaceuti
cals 
Type of innovation 
(process/ product) 
Process  Process  Process/Product  Product 
Changes in pro‐
duction costs 
Slight decrease  Increase  Decrease  Increase 
Input of biomass  High  High  Low  Very low 
State of technical 
development 
Early diffusion/ 
demonstration 
plants 
Early diffusion  Diffusion  Diffusion 
 
Scenarios  
Scenarios provide a structured description of possible future development paths, depending 
on current and future framework conditions. For the analysis of the production and 
employment effects of biotechnology diffusion in Germany with a time horizon to 2020, 
the following set of scenarios is used: 
• a reference scenario for biotechnology diffusion, based on literature and expert 
judgements  
• a "high-diffusion" (HD) scenario with favourable conditions for higher diffusion 
paths of biotechnology  
• a hypothetical basis scenario with no further diffusion of biotechnology in the 
various application fields. 
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In the reference scenario, assumptions for prices of oil and biomass are mainly based on 
OECD projections. The oil price is set at 70 US$/bbl (2005 real prices), the price for wheat 
is 120 €/t, for sugar 32 €/t and for lignocelluloses 55 €/t.2 The HD scenario reflects a 
higher price ratio of fossil to renewable resources, the real oil price is set at 100 US$/bbl 
based on IEA estimates. Prices for biomass increase due to higher production costs, which 
depend partly on energy costs (e.g. fuel for tractors). But overall the price increases remain 
beneath the higher oil prices (wheat 126 €/t; sugar 33 €/t; lignocelluloses 55 €/t). In 
addition to these price assumptions, more favourable policy strategies for diffusing 
biotechnological processes are assumed. The sector-specific assumptions for the 
quantitative mapping of the scenarios in the four application fields are summarized in 
chapter 4.  
As the aim of this study is to explore the effects of further biotechnological diffusion, all 
values are subsequently compared to those calculated under the basis scenario, in order to 
single out the impacts of each of the scenarios with biotechnology diffusion.  
 
Input-Output modelling of biotechnological change 
For each scenario an input-output framework is set up to account for direct and indirect 
production and employment effects associated with the diffusion of biotechnology. The 
plain input-output model (IO model) used in this study is based on the input-output tables 
produced by the Federal Statistical Office for the year 2005. They divide the German 
economy into 71 production and service sectors and six end-user sectors (including, among 
others, private and state consumer demand and export). Employment impacts are 
calculated by multiplying the biotechnology-related production volume and employment 
coefficients (gainfully employed persons per unit of gross production value). Since the 
scenarios analyzed refer to the year 2020, in principle one should endeavour to project the 
input–output table to this year. However, since the official macro aggregates necessary for 
the estimation are not available, the dynamic dimension is not regarded. Instead, the results 
should not be interpreted as directly representative of a hypothetical year 2020, but as 
“what if” scenarios. In order to avoid overestimations of employment impacts, labour 
productivity improvements were estimated on developments between 1995 and 2005 for 
all scenarios. Moreover constraints on domestic availability of surplus land are considered, 
 
2 All estimates are based on 2005 real prices. 
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as land availability and food needs will limit the growth of agriculture (OECD/FAO 2008). 
Supply and demand developments for biomass were estimated on the basis of various 
studies (e.g. SRU 2007, Nusser et al. 2007b). The domestic availability of biomass from 
food crops is set at 70% in the reference scenario and 80% in the HD scenario. For 
lignocellulose production on non-crop land (e.g. unused portions of food plants such as 
corn stover or industrial waste products) is presupposed.  
IO models are sometimes considered inappropriate for long-term studies as the IO 
production function does not allow for substitutions among inputs and technological 
change.3 But as has been demonstrated in several studies (e.g. Faber et al. 2007), 
adjustments can be made. In this study, such adjustments were made for the sectors with 
biotechnological diffusion. A new "biotechnology" sector is introduced into the IO model 
for each application field, to study the biotechnological effects in detail. If the original 
structure is expanded, a considerable amount of structural information can be consistently 
derived about the flow of goods and services, intermediary effects and induced and indirect 
employment. A new sector in an IO model is defined by the amounts obtained from all 
other sectors, the amounts delivered to all other sectors, imports to and added value from 
the new sector. Inputs to the new sector are inserted into a new additional column to the 
table, outputs from the new sector into a new row. In general, IO sectors should have a 
rather high degree of homogeneity. As a variety of technologies, resources and products 
are involved in each sector, a more disaggregated analysis for biotechnology applications 
(e.g. for different types of biopolymers) is useful. In order to build an average IO vector, 
shares of different products or resources (e.g. share of bioethanol from wheat) are assumed. 
For each scenario, detailed estimates are made for the biotechnology development from the 
survey. 
Besides positive production and employment effects from increasing utilization of 
biotechnology, negative impacts may occur, among others due to the (relative) "shrinkage" 
of conventional production and research methods (e.g. fossil-based petrol). For an 
investigation of the net effects, the different investments in the substituted fossil products, 
their operation and management as well as their different import quotas and costs are 
additionally determined by literature and expert information.  
 
 
3  For a detailed discussion, see Faber et al. (2007). 
 10 
 
Different types of change compared to conventional methods are distinguished to analyze 
the various economic impact mechanisms (section 2). Biotechnology may require changes 
in production processes which result in 
• lower/higher input coefficients for specific inputs (e.g. for energy in the case of 
biopolymers) or different related investment volumes; 
• a more efficient use of all inputs due to process innovation; 
• substitutions between inputs (e.g. biomass instead of oil.). 
In the first two cases production costs may differ and lead to reactions on the demand side 
via changes in product prices or increases in wages. In this study it is assumed that lower 
production costs directly result in price reductions and eventually to a higher disposable 
income. In contrast, higher production costs are recollected from private consumers 
through an increase in general taxation of the equal amount, reflected by a reduction in the 
disposable income of consumers and therefore in aggregate demand. In order to capture the 
consumers' substitution behaviour, price and income elasticities are adapted from Neuwahl 
et al. (2007).  
Apart from changes in the input structure, product innovations enabled by biotechnology 
increase the quality and variety of goods and may open up new markets. But integrating 
product innovations into modelling frameworks is difficult (Pianta 2005), since the 
additional diffusion in complementary to existing products is unclear. Moreover, in the 
present case of biopharmaceuticals, the demand side is largely driven by regulations. These 
influence the financing of new products and the degree to which markets may grow. Even 
if innovations lead to rising pharmaceutical markets, it is open whether higher health costs 
induce lower consumption for other goods and services or can be interpreted as an 
additional demand. Therefore, the modelling approach distinguishes between two cases. In 
the first case, the additional expenditures are compensated by falling consumption due to 
lower disposable income. In the second case, an additional demand for the pharmaceutical 
product innovations arises with no reductions for other consumption goods. In 
consequence, saving rates are lower. While both cases represent a maximum development, 
no plausible estimate for a mixture of these cases can be given yet.  
The bottom-up technology information and projections are derived from techno-economic 
studies and expert judgements in combination with scenario assumptions. Cost degressions 
caused by learning-effects are also taken into account. A critical step in this methodology 
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is the selection of the experts. On the one hand, employees from biotech-active firms have 
possibly the highest expertise, but on the other hand, overoptimistic views of experts are 
thinkable, as most of the business models of these stakeholders rely totally on successful 
developments in biotechnology (Hopkins et al. 2007). In this study, experts were selected 
on the expertise dimension and on the dimension of the perspective on the biotechnology 
chain. Around half of the 40 interviewed experts were from firms which use biotechnology 
and conventional technology methods. These users of biotechnology have a high expertise 
concerning the advantages, disadvantages and changes through biotechnology and 
probably a more objective view, as they do not depend heavily on biotechnological 
success. The other half of experts was selected along the value chain and included plant 
manufacturers, researchers and core biotech firms.4  
The necessary investment ratios are derived from literature, technology databases and 
expert information. The investment volumes were divided into annual investment streams 
and then assigned to the relevant supply (sub-) sectors (e.g. plant construction, mechanical 
engineering) and integrated in the input-output model. In order to ascertain employment in 
the cultivation of renewable raw resources in German agriculture, specific employment 
factors were constructed based on the German agricultural statistics. 
Despite these various model adjustments, the reader should bear in mind some limitations 
of the adopted modelling approach: firstly, the two important impact mechanisms of 
product innovations and changes in international competitiveness are taken explicitly into 
account, but they could only be considered by rough estimates at a highly aggregated level. 
More detailed analysis, e.g. for potential first-mover advantages, would be desirable. 
Secondly, changes in the international demand and supply side of biomass could only be 
partially considered in the analysis as it was outside the scope of the underlying study to 
investigate worldwide developments. Thirdly, innovation and diffusion dynamics and their 
economic outcomes could not be regarded explicitly and the diffusion is estimated 
exogenously. Besides, price effects are included only partially, but this impact mechanism 
seems of minor importance in the chosen application fields of biotechnology. In spite of 
these limitations, the methodology used is able to provide some interesting and well-
founded insights regarding the economic effects of biotechnology. 
 
 
4 A list of participating organisations is available from the author. 
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4.  Technological developments and sectoral input variations 
In the subsequent analysis, potential diffusion rates of biotechnology and variations in 
sectoral inputs are assessed for all application sectors. The production costs are calculated 
as important intermediate results to estimate the input coefficients and demand variations. 
Detailed figures are presented in the annex tables 4 to 7.  
 
Bioethanol  
The scenarios introduce different replacement shares of conventional fuels for bioethanol. 
The major part is produced by first generation bioethanol from wheat and sugar beet. 
Although second generation technologies are still at demonstration plant stage today, a 
partial diffusion of bioethanol from fermentation of lignocellulose feedstock is assumed. 
The reference scenario is based on interim plans of the EU's new Renewable Energy 
Directive of 2008, which obliges Member States to ensure that 10% of their transport fuel 
comes from renewable sources, only 3/5 of which are allowed to come from first 
generation biofuels. Hence, bioethanol from wheat and sugar take a share of 6% of total 
fuels and another 1.25% are expected from lignocellulose feedstock. The high-diffusion 
scenario reflects the ambitions of the German government in 2008 of a 14% share. The 
offsetting of oil-derived fuels with bioethanol was made on an energy equivalence basis. 
The inputs to the bioethanol sector were constructed based on process chain data derived 
from the "Wheels to Wheels" study (Concawe 2006) combined with scenario assumptions 
for prices for oil and renewables. The main bioethanol conversion process costs are 
decreased slightly in the reference scenario compared to data from Concawe (2006), and to 
a higher degree in the HD scenario, by introducing learning effect cost reductions on 
capital costs, labour costs and other fixed operating costs for the year 2020. The substituted 
petrol sector was constructed by a disaggregation of the mineral oil sector using estimates 
for the input share of oil in each scenario (MWV 2006). In the reference and HD scenario 
bioethanol production costs are higher than for petrol and lead to increasing fuel prices and 
consequently to lower final demand. 
As production costs for bioethanol in Germany are also higher than in some other 
countries, e.g. Brazil, international competitiveness is limited. Moreover, a total domestic 
production of the demand for bioethanol seems unrealistic, due to land availability 
constraints. Estimations from literature for import quotas in Germany vary between 20 to 
50% (WI/RWI 2008; Nusser et al. 2007b). For both scenarios the import quota is set at 
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30% and the export quota at zero. For the substituted conventional fuels, Germany is 
instead a net exporter. But important differences between oil-based fuels and bioethanol lie 
in the different import quotas of the value chain. While oil is totally imported, biomass for 
bioethanol is at least partly produced domestically. 
 
Biopolymers  
Currently the diffusion of biotechnologically produced polymers is low. But increasing oil 
prices, growing interest in renewable resources, concerns regarding greenhouse gas 
emissions and improved properties (e.g. in surface finish) have created a renewed interest 
in biomass-based polymers5. Hence, techno-economic studies (e.g. Crank et al. 2004) and 
the interviewed experts in this study estimate an increasing market penetration of 
biopolymers. A share of 4% of total polymers is expected in the reference scenario. A main 
driver for diffusion of biopolymers is the ratio of oil prices to biomass, as the price 
difference of the respective main input strongly affects the economic advantage of 
biopolymers. In the high diffusion scenario biopolymers have a share of 8% of all 
polymers produced.   
The international competitiveness of domestic enterprises with regard to biopolymers is 
rather unclear. Although Germany may have disadvantages due to the domestic availability 
of cheap biomass, patent analysis from Beucker/Marscheider-Weidemann (2007) and 
expert judgments state a high technological competitiveness. As it cannot be determined 
which of these contradictory arguments will dominate, no differences between the trade 
balances of oil-based polymers and biopolymers occur in either scenario. The inputs to the 
biopolymer sector were constructed from process chain data derived from Patel et al. 
(2006) combined with expert judgments and the scenario assumptions for prices. In the 
reference scenario biopolymers have slightly lower production costs of about 3%, in the 
high-diffusion scenario the cost advantage is about 20%, due to higher oil prices. For the 
input structure (e.g. demand for labour, auxiliaries) only minor differences apart from the 
substitution of oil are expected, so the main drivers for economic impact are the slight cost 
decline and the substitution of fossil resources. 
 
 
5  Only the biotechnologically produced polymers are considered, other polymers from biomass (e.g. 
starch) are not included. 
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Biotechnologically produced fine and specialty chemicals 
In fine and specialty chemicals biotechnology processes can have several advantages over 
traditional chemical synthesis, including more specific reactions, less demanding 
production conditions (such as lower temperature and pressure, and milder pH conditions) 
and lower energy inputs, waste, and environmental impacts. According to expert 
judgements the share of biotechnologically produced products is expected to increase from 
about 5% in 2005 (Nusser et al. 2007b; von Armansperg/Patel 2006) to 10% in the 
reference scenario and to 15% in the HD scenario. The economic impact may differ 
between these heterogeneous products. In some cases, improved functionalities of 
fine/specialty chemicals lead to a higher product quality. While significant quality 
improvements of a product may have similar effects like product innovations on creating 
new markets (Tether 2003), this seems not to be the case for fine/specialty chemicals. 
According to expert judgements, the creation of new markets or a significant expansion of 
existing markets are rather unlikely. Therefore in the scenarios no additive impulses of 
product innovations are considered and the impact of biotechnology is modelled as a pure 
process innovation. A significant impact lies in a more efficient production, as the process 
steps may be reduced (e.g. riboflavin). Moreover, advanced biotechnology-facilitated 
production processes are likely to reduce value inputs of energy and inputs of refined oil 
products, e.g. biotechnology catalysts using plant-derived feedstock instead of petroleum-
based feedstock in the production of chemicals and synthetic fibres. In the reference 
scenario the production cost reduction averages 10% and splits up in decreases for various 
inputs. In the HD scenario the production costs for biotechnological products are 15% 
lower than for traditional chemicals, due to learning effects.  
 
Biopharmaceuticals 
The pharmaceutical sector is currently the main application field for biotechnology firms. 
Therapeutics developed using biotechnology can be classified in different groups; one 
separation can be achieved by differentiating large molecule biopharmaceuticals and small 
molecule therapeutics. Due to lack of data, the impact of biotechnology on the 
development of small molecules cannot be assessed. However, the analysis of 
 15 
 
                                                           
biopharmaceuticals6 compared to chemical substances offers interesting insights. The 
biopharmaceutical share of all new pharmaceutical compounds (new molecular entities or 
NMEs) that received market approval increased from 2% to about 15% in 2005 (OECD 
2009). But according to analyses by Reiss et al. (2007) and OECD (2009) based on clinical 
trial data, a slight increase in the share of biopharmaceuticals for new molecular entities 
can be expected in the next years. Nevertheless, the turnover share of biotechnology can be 
expected to grow stronger as most biopharmaceuticals belong to high-price segments. 
According to Reiss et al. (2007), the turnover for an average biopharmaceutical tripled 
between 1995 and 2005. The interviewed experts confirm the expectation of a slight 
increase in biopharmaceutical shares of NMEs and a more dynamic growth in the 
production value share. The median for the biopharmaceutical production value share is 
estimated to grow from about 11% in the year 2005 (VFA 2007) to 24% in the reference 
scenario for 2020. Assuming a more dynamic technological development without further 
restrictions on the regulatory side, the share grows to 32% in the HD scenario. These 
developments are likely to increase total output in pharmaceutical products as 
biopharmaceuticals are often developed for different types of diseases than chemical 
substances and consequently have a more additional character. Therefore in the scenarios 
production growth of biopharmaceuticals leads to a higher pharmaceutical output. To 
model reactions on the consumer side, additional assumptions have to be made for health 
care costs increases in consequence of higher sales of pharmaceuticals. In the literature 
some examples for savings in total therapy costs through biopharmaceuticals exist (IPTS 
2007). But the contrary is also conceivable, e.g. in case of longer, but unhealthier longevity 
(IPTS 2007). On an aggregated level, no clear judgement can be made yet (Rosenberg-
Yunger 2008). As mentioned in the scenario descriptions, higher health care costs are 
assumed in the amount of higher pharmaceutical output, which induce reductions for other 
consumption goods and services. An additional alternative analysis is conducted with the 
assumption of an additional market demand and respectively lower savings rates. 
According to expert judgements, differences in the input structure for biopharmaceuticals 
and chemicals mainly occur through higher production costs for biopharmaceuticals, while 
no major differences in the resource intensity of the development of biotechnology 
products are expected (Hopkins et al. 2007).  
 
 
6  Biopharmaceuticals are defined as ”[…] recombinant products such as interferon, interleukin, growth 
factors; blood factors, hormones and other peptides and proteins; antibodies, immunotoxines, and 
immunoconjugates“ (Reiss et al. 2007, p. 45). 
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5.  Net production and employment effects 
The above described technological survey and derived parameters for the IO model are 
used to calculate the impact of biotechnological development and diffusion on production 
and employment. Table 2 and table 3 show the net production and employment results. For 
easier handling of the results, the 71 sectors of the IO table are aggregated to eight macro 
sectors. The production and employment impacts are mostly slightly positive but differ 
greatly between the various application fields.  
 
Table 2: Net production impacts (in € m) in 2020 for the reference and high diffusion 
scenario and different application sectors compared to the basic scenario 
  Biopolymers Bioethanol 
Fine and spe-
cialty chemicals
Biopharmaceuticals 
  
Refe-
rence 
HD 
Refe-
rence 
HD 
Refe-
rence 
HD 
Refe-
rence 
Alternative
reference* 
HD 
Agriculture 524 1019 404 741 54 85 -24 7 -39 
Chemical industry 1 3 0 2 -11 -24 3940 -135 6404 
Pharmaceutical 
industry 
-343 -1145 48 133 -479 -1148 -161 3948 -167 
Capital goods 
industry 
78 144 60 146 -21 -49 58 201 84 
Energy, water -65 -167 4 17 -17 -37 -3 -5 -9 
Other industries -50 -177 -48 -288 -43 -92 103 514 135 
Building industry 66 124 18 50 -11 -25 24 72 35 
Services 89 140 -24 268 -25 -32 -1627 934 -2680 
Total 299 -60 462 1,069 -554 -1,322 2,310 5,536 3,761 
* In the alternative calculation for biopharmaceuticals no increase in health care costs is 
assumed. 
 
The impact is mainly positive for bioethanol and biopolymers. The respective net 
production results vary across application fields and scenarios by between about € -60 and 
€ 1,070 m, the employment impact lies between around 3,000 and 9,000 jobs. The higher 
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effects in the HD scenario result from the higher oil price. Hence, the total economic 
burden of bioethanol usage is reduced and in the case of biopolymers private consumption 
increases. For biopharmaceuticals on the contrary the production impact is slightly positive 
but the employment effect is negative in the reference and HD scenario, as most of the 
negative effects occur in the labour-intensive service sectors. The employment impact is 
only positive in the "alternative" scenario, where the output growth of (bio-)pharma-
ceuticals is modelled additively and is not compensated by less consumption due to higher 
health costs as in the reference scenario. For fine/specialty chemicals the production and 
employment effects are negative. This is not surprising, as biotechnology mostly leads to 
process innovations in the sector without big changes in the input structures. Such process 
innovations tend to lead to negative employment effects (e.g. Pianta 2005).  
 
Table 3: Net employment effects (in number of jobs) in 2020 for the reference and 
high diffusion scenario and different application sectors compared to the 
basic scenario 
  Biopolymers Bioethanol 
Fine and spe-
cialty chemicals
Biopharmaceuticals 
  
Refe-
rence 
HD 
Refe-
rence 
HD 
Refe-
rence 
HD 
Refe-
rence 
Alternative
reference* 
HD 
Agriculture 2,865 5,267 2,906 5,236 391 614 -255 74 -425 
Chemical industry -267 -495 42 116 -296 -902 -141 -118 -146 
Pharmaceutical 
industry 
2 4 1 3 1 1 6,575 6,588 10,681 
Capital goods 
industry 
402 737 341 780 -95 -225 472 955 720 
Energy, water -136 -360 5 27 -26 -57 -15 -20 -31 
Other industries -157 -427 160 599 -217 -452 -146 1786 -343 
Building industry 733 1,377 198 554 -126 -275 266 797 387 
Services 572 886 -670 1,997 -192 -169 -17,604 9,139 -28,999 
Total 4,015 6,990 2,982 9,313 -560 -1,466 -1,0847 19,202 -18,156
* In the alternative calculation for biopharmaceuticals no increase in health care costs is 
assumed. 
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Overall, the net effects are small in most cases. This can be explained by the limited 
differences in the value chain and trade balances between biotechnological and 
conventional research and production. The sectoral results show that indirect effects are of 
great importance for the results. Structural change is concentrated on a few sectors, a 
significant part of the effects occur in agriculture and service sectors as consequence of 
higher input for biomass and changes in consumption, which are mainly reflected in the 
demand for services. So while biotechnological methods are dominantly used in industrial 
sectors, interestingly, the effects also emerge in the primary and tertiary sectors.  
 
In the sensitivity analysis, several parameters are checked for their uncertainty and their 
effect on the results (annex figure 2). Since similar effects are expected for net production 
results, only the sensitivity analysis for net employment is presented here. Sensitivity runs 
with upper and lower values for certain parameters, derived by literature or expert 
information, are conducted. The sensitivity analysis indicates that the results are most 
sensitive to the trade balance and diffusion and less affected by cost and consumption 
structures. The results display a somewhat higher robustness and only in few cases the 
prefix of the net impact changes.  
 
6.  Conclusion 
This paper has analyzed the economic impacts of different diffusion paths of 
biotechnology in some major application fields. Bottom-up technology information from 
literature, expert judgements and explicit scenario assumptions for various impact factors 
are combined and integrated into an input-output framework to calculate direct and indirect 
production and employment effects. The results indicate that biotechnology is on its way to 
becoming increasingly relevant for the economy and is likely to gain in importance in all 
analyzed application sectors in the next 10 to 15 years. But the impacts on net production 
and employment differ greatly between the different sectors; they vary between negative 
and positive results. In the case of bioethanol and biopolymers, the substitution effects are 
highly favourable through lower import quotas and higher labour intensities in the 
respective value chain. For biopharmaceuticals the impacts on employment are only 
positive, if there are additive impulses of product innovations, or if a high international 
competitiveness can be achieved in these sectors.  
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It is clear that the above analysis draws only a limited picture of the economic effects of 
the utilization of biotechnology, as not all impact mechanisms could be studied in desirable 
depth (e.g. first-mover advantages). It also has to be kept in mind that the net production 
and employment impact draw only a part of the whole picture. Moreover, the background 
of an increasing outsourcing of conventional industrial production jobs to eastern Europe 
and Asia has to be regarded; many jobs can be lost due to these relocations. Compared 
with such a reference development, even low net employment effects can be positively 
judged, if biotechnology supports the competitiveness of domestic production plants.  
Nevertheless, the methodology used is able to provide some well-founded and interesting 
insights as the results indicate that the indirect and induced employment effects are rather 
high and exceed the direct employment effects. This highlights the importance of a 
methodology which considers such impacts. Additionally, the disaggregated analysis of the 
various applications shows that the impact mechanisms differ greatly between the 
application fields. A detailed bottom-up approach is therefore necessary for an appropriate 
modelling. 
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Annex 
Figure 2: Sensitivity analysis for the employment effects in dependence of parameter 
variation (Reference = 100%)  
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Table 4: Bioethanol production costs (in €/t) 
 Reference scenario HD scenario 
(Cost) parameters Wheat 
Sugar 
beet Lignoc.
Aver-
age Wheat 
Sugar 
beet Lignoc. 
Aver
-age 
Feedstock cost in €/t 120 32 53 - 126 33 55 - 
t feedstock per t bio-
ethanol 
3 13 4 - 3 13 3 - 
Costs per t bioethanol 404 422 187 355 425 442 170 334 
..thereof transport costs 4 17 12 8 4 17 12 8 
Chemical 
auxiliaries/lubricants 
22 32 27 24 40 44 30 37 
Electricity consumption 33 47 40 37 60 66 46 56 
Labour costs 20 16 29 22 22 18 28 23 
Overhead 7 5 87 26 7 6 83 35 
Annual debt service 42 32 93 53 44 33 89 59 
Capital costs 63 48 139 79 65 50 133 88 
Co-product revenue -112 -71 - -79 -117 -75 - -70 
Total production costs 1,414 1,488 943 1,282 545 587 578 562 
Highlighted values directly sum up to total costs. Average costs result from the shares of 
the feedstock of the additional ethanol production. 
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Table 5: Biopolymer production costs (in €/t) 
 Reference scenario HD scenario 
(Cost) parameters PLA PHA PDO Average PLA PHA PDO Average
Feedstock cost in €/t 120 120 120  126 126 126  
t feedstock per t 
biopolymer 
2 5 3  2 5 3  
Costs per t biopolymer 288 600 408 393 302 630 403 408 
..thereof transport costs 3 6 4 4 3 6 4 4 
Chemical 
auxiliaries/lubricants 
539 480 214 411 585 535 213 444 
Electricity consumption 178 147 71 132 242 205 89 179 
Labour costs 35 35 35 35 33 34 31 33 
Overhead 190 120 110 140 181 117 96 131 
Annual debt service 108 114 91 121 107 117 83 129 
Capital costs 162 172 137 179 161 175 124 193 
Co-product revenue -86 -180 -122 -130 -98 -205 -139 -136 
Total production costs 1,414 1,488 943 1,282 1,513 1,608 899 1,340 
* Highlighted values directly sum up to total costs. Average costs result from the shares of 
the biopolymer types (one third).  
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Table 6: Input structure of biotechnological fine/specialty chemicals and substitutes 
  
Biotechnology 
(reference 
scenario) 
Biotechnology 
(HD scenario) 
Chemical 
substitute 
Agriculture 5.5% 5.3% 0.0% 
Other feedstock/auxiliaries/lubricants 46.1% 42.6% 58.2% 
Capital costs 2.5% 2.3% 3.5% 
Waste disposal 0.9% 0.8% 1.3% 
Electricity consumption 1.2% 1.1% 1.8% 
R&D inputs 0.7% 0.7% 0.5% 
Services 17.4% 17.4% 17.4% 
Labour costs 10.9% 10.0% 12.5% 
Other value added (a. o. profits) 4.8% 4.8% 4.8% 
Production costs 90.0% 85.0% 100.0% 
Cost decreases (=>higher consumption) 10.0% 15.0%  
Total 100.0% 100.0% 100.0% 
 
Table 7: Input structure of biopharmaceuticals and substitutes 
  Biopharmaceuticals 
Pharmaceutical 
substitute 
Chemicals 5.0% 10.8% 
Other industry inputs 38.1% 21.5% 
R&D inputs 12.7% 10.2% 
Other services 17.1% 16.0% 
Capital costs 5.7% 3.3% 
Labour costs 34.4% 26.3% 
Other value added (a. o.profits) 11.9% 11.9% 
Production costs 125.0% 100.0% 
Cost increases (=> lower consumption) -25.0% 0.0% 
Total 100.0% 100.0% 
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